MGO One Seven LLC Acquires 4,449 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• MGO One Seven LLC increased its holdings in Johnson & Johnson by 5.8% to own 80,891 shares worth $13.4 million, highlighting institutional investor interest in the stock.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, with a current yield of 3.11% and a payout ratio of 55.61%.
• The stock has received mostly positive analyst ratings, with the consensus price target set at $174.50 and various ratings reflecting a trend toward buying.

MGO One Seven LLC lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,891 shares of the company's stock after purchasing an additional 4,449 shares during the period. MGO One Seven LLC's holdings in Johnson & Johnson were worth $13,415,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of JNJ. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC boosted its position in shares of Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares in the last quarter. Potomac Fund Management Inc. ADV bought a new position in shares of Johnson & Johnson during the fourth quarter worth $625,000. Meeder Advisory Services Inc. boosted its position in shares of Johnson & Johnson by 2.4% during the fourth quarter. Meeder Advisory Services Inc. now owns 37,359 shares of the company's stock worth $5,403,000 after purchasing an additional 882 shares in the last quarter. Finally, RFG Bristol Wealth Advisors LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth $928,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on JNJ shares. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. UBS Group boosted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $2.59 during trading on Friday, reaching $167.33. 8,914,735 shares of the company's stock were exchanged, compared to its average volume of 8,384,981. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market capitalization of $402.99 billion, a P/E ratio of 17.90, a PEG ratio of 2.10 and a beta of 0.41. The business has a 50 day moving average price of $157.46 and a 200-day moving average price of $156.60. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the business earned $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.1%. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.